AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7425360
Drug: Methohexital 25
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital 25 mg/kg, rectally
Trial: 7425360
Drug: Methohexital 30
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital 30 mg/kg, rectally
Trial: 7425360
Drug: Methohexital (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (all doses)
Trial: 30309264
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor binding protein-1 levels
Trial: 24007304
Drug: Mavoglurant (AFQ056)
RxNorm normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavoglurant (AFQ056) 25 mg bid to 100 mg bid
Trial: 19571161
Drug: quercetin+vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quercetin+vitamin C (166mg+133mg/capsule)
Trial: 19571161
Drug: alpha‐lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐lipoic acid (300mg/capsule)
Trial: 17533206
Drug: Structured pharmacist
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured pharmacist medication history interview with assessment and generation of a postoperative medication order form
Trial: 17533206
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (nurse‐conducted medication histories and surgeon‐generated medication orders)
Trial: 11347834
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Enoxaparin)
Trial: 8255974
Drug: Isoprenaline infusion
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline infusion (0.5-3.0 micrograms/min)
Trial: 8255974
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg atenolol (beta 1 antagonist)
Trial: 8255974
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nadolol (beta 1/beta 2 blocker)
Trial: 8255974
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nadolol (beta 1/beta 2 blocker)
Trial: 3318433
Drug: Aspirin 900
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 900 mg four times daily
Trial: 23190785
Drug: Control vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccines (MenC‐TT coadministered with DTPa‐HBV‐IPV/Hib)
Trial: 12914871
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 to 400 mg twice daily)
Trial: 31160249
Drug: Cediranib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib (30 mg orally, once daily)
Trial: 19709417
Drug: Oxaliplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin (120 mg/m2, d1) + Dacarbazine (175 mg/m2, d13)
Trial: 9692689
Drug: omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 10 mg o.m.
Trial: 9692689
Drug: antacid/alginate liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antacid/alginate liquid 10 mL q.d.s.
Trial: 11465413
Drug: O/W emulsion-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O/W emulsion-based cream for lidocaine
Trial: 11465413
Drug: Both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both active treatments (microemulsion and O/W emulsion)
Trial: 9611474
Drug: Subgingival application
RxNorm normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival application of 25% metronidazole gel
Trial: 9611474
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of scaling and metronidazole gel application
Trial: 7834161
Drug: Caffeine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.5 mg.kg‐1 body weight)
Trial: 7834161
Drug: Ethanol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (25 ml in 150 ml of grapefruit juice)
Trial: 3202091
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (3 mg RE or 10,000 IU daily for 4 months)
Trial: 3202091
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 4 months)
Trial: 29171002
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of carbamazepine and oxcarbazepine/phenytoin
Trial: 23860530
Drug: Aprepitant (day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg) with dexamethasone (12 mg on day 1, 4 mg on days 2 and 3)
Trial: 23860530
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with dexamethasone (20 mg on day 1, 8 mg on days 2 and 3)
Trial: 23860530
Drug: Aprepitant (day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg)
Trial: 19952817
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g.kg body mass
Trial: 19952817
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (placebo; PL trial) 0.045 g.kg body mass
Trial: 18639418
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser treatment
Trial: 17026559
Drug: Colon preparation
RxNorm normalized name: porcine colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon preparation on the day of colonoscopy (on-the-day group)
Trial: 17026559
Drug: Colon preparation
RxNorm normalized name: porcine colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon preparation the night before colonoscopy (previous night group)
Trial: 12968982
Drug: Furosemide (F)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (F) 0.5 mg kg(‐1) intravenously
Trial: 11469297
Drug: Aqueous calcium
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous calcium hydroxide suspension
Trial: 18388097
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (500 mg every 8 hours for 49 days)
Trial: 16024973
Drug: G/A or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/A or A/A genotypes
Trial: 16024973
Drug: G/A and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/A and A/A patients
Trial: 31246057
Drug: Emotion-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion-focused therapy for trauma
Trial: 31246057
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in primary adaptive emotions from early to late treatment sessions
Trial: 26457986
Drug: Fludarabine (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (not specified if alone or in combination)
Trial: 26457986
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy that induces a complete remission (CR)
Trial: 26457986
Drug: FC-based second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FC-based second-line therapy (including rituximab in 20%) or stem cell transplant
Trial: 22158147
Drug: Vardenafil (VAR)
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vardenafil (VAR) 10 mg on demand
Trial: 20332288
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for chronic pain
Trial: 18053943
Drug: Low dose,
RxNorm normalized name: Aspirin Low Dose, 81 mg oral tablet, chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose, 3 mg (Group A)
Trial: 18053943
Drug: High dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose, 10 mg (Group B)
Trial: 2960296
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Trial: 2960296
Drug: Portal vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Trial: 2960296
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to hepatic arterial infusion after portal vein infusion
Trial: 21569996
Drug: Combination-therapy trastuzumab
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-therapy trastuzumab plus docetaxel (H+D)
Trial: 21569996
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy of single-agent trastuzumab followed by docetaxel (H→D)
Trial: 21569996
Drug: Monotherapy trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy trastuzumab in H→D group
Trial: 21569996
Drug: Retrospective analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective analysis of trastuzumab treatment beyond progression
Trial: 11057795
Drug: Dopexamine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (both doses)
Trial: 8399607
Drug: Intraperitoneal vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal vancomycin (1 g) and oral pefloxacin (400 mg b.i.d.)
Trial: 8399607
Drug: Intraperitoneal vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal vancomycin (1 g) and gentamicin (80 mg loading dose, followed by 15 mg/2 L)
Trial: 6576742
Drug: Wet aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wet aerosol salbutamol (10 mg, 4 x 0.5 ml of 0.5% standard solution)
Trial: 6576742
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler (MDI) salbutamol (800 micrograms, 8 x 100 micrograms)
Trial: 31104629
Drug: Monetary incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monetary incentive of 2.00 for every maternal client attending postnatal care within 48 h of delivery (treatment group)
Trial: 31104629
Drug: Monetary incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monetary incentive of 2.00 for every neonatal client attending postnatal care within 48 h of delivery (treatment group)
Trial: 18070468
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d and aspirin 100 mg/d plus cilostazol 200 mg/d
Trial: 18070468
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d and aspirin 100 mg/d
Trial: 10988282
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg twice daily for 1 week, then 50 mg twice daily for 5 weeks)
Trial: 10988282
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg daily) with Losartan
Trial: 10988282
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg daily) with Captopril
Trial: 8989058
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (subcutaneous anesthetic infiltration)
Trial: 6739139
Drug: Apalcillin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalcillin 500 mg
Trial: 6739139
Drug: Apalcillin 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalcillin 1000 mg
Trial: 6739139
Drug: Apalcillin 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalcillin 2000 mg
Trial: 6739139
Drug: Apalcillin 3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalcillin 3000 mg
Trial: 6739139
Drug: Apalcillin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalcillin (all doses)
Trial: 31317029
Drug: Lycopene 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene 7 mg daily
Trial: 31317029
Drug: Lycopene 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene 30 mg daily (formulation 1)
Trial: 31317029
Drug: Lycopene 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene 30 mg daily (formulation 2)
Trial: 31317029
Drug: Dark Chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark Chocolate (DC) with 7 mg lycopene
Trial: 26140823
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) for SAD
Trial: 21850574
Drug: Safinamide 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide 300 mg administered once daily under fasting conditions
Trial: 21850574
Drug: Tyramine 200
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine 200 mg administered alone
Trial: 21850574
Drug: Tyramine 50
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine 50 mg and 100 mg administered on days 5, 6, and 7 respectively
Trial: 20015429
Drug: Classical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical therapy of thread‐drawing method (control)
Trial: 12857474
Drug: Plasma Exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Exchange (PE) + Continuous Renal Replacement Therapy (CRRT)
Trial: 12857474
Drug: Basic Treatment
RxNorm normalized name: Basic FGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic Treatment
Trial: 26935578
Drug: Cilengitide (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide (2000 mg IV twice weekly) with metronomic temozolomide (60 mg/m²) and procarbazine (50 or 100 mg)
Trial: 22853980
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m(2)) plus Ramucirumab (10 mg/kg)
Trial: 22853980
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m(2)) plus Placebo
Trial: 17409312
Drug: Agalsidase beta,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agalsidase beta, 1 mg/kg biweekly for up to 54 months
Trial: 29649631
Drug: Multifactorial behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial behavioral and medication management intervention delivered via telephone, including up to 36 monthly educational modules, home blood pressure monitoring, and electronic medication management recommendations.
Trial: 26516434
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (17‐α hydroxyprogesterone caproate)
Trial: 24081245
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (prednisone, azathioprine, N-acetylcysteine)
Trial: 20851818
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs)
Trial: 16503543
Drug: Sufentanil intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil intravenous analgesia (1 microg/ml)
Trial: 16503543
Drug: Fentanyl intravenous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl intravenous analgesia (10 microg/ml)
Trial: 9480650
Drug: Pefloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (800 mg daily for 7-10 days)
Trial: 9480650
Drug: Routine antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotics (benzylpenicillin, ampicillin, erythromycin)
Trial: 3679106
Drug: Supportive art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive art therapy group (10 weeks)
Trial: 30288918
Drug: Intervention arm
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention arm (PSA tests and digital rectal examinations)
Trial: 25880054
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day omega‐3 fatty acids plus 400 IU/day vitamin E (OE)
Trial: 25880054
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day omega‐3 fatty acids plus vitamin E placebo (OP)
Trial: 21497319
Drug: 10-week supervised
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week supervised hip flexor stretching program (twice-daily, supervised twice weekly)
Trial: 17438512
Drug: Low-dose local
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose local vaginal estrogen therapy
Trial: 9825751
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg triple helical collagen type II
Trial: 7813220
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dose of doxycycline
Trial: 1209742
Drug: Topical ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ampicillin (0.5-1 g into the wound before closure)
Trial: 7352522
Drug: Room air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room air administration
Trial: 28424185
Drug: 3.9 g
RxNorm normalized name: aspirin 3.9 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day for 6 months
Trial: 28424185
Drug: Placebo (4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4.2 g oleate per day for 6 months)
Trial: 21883635
Drug: Procedural sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedural sedation with etomidate as the sole agent
Trial: 9445321
Drug: Ebselen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen (150 mg BID for 2 weeks)
Trial: 7614505
Drug: cilazapril (CLZ)
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (CLZ) 1‐2.5 mg once daily (n = 221)
Trial: 7614505
Drug: captopril (CPT)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: captopril (CPT) 25‐50 mg three times daily (n = 108)
Trial: 2515753
Drug: Once‐daily lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐daily lithium carbonate (Priadal)
Trial: 2515753
Drug: Twice‐daily lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice‐daily lithium citrate (Litarex)
Trial: 983179
Drug: EMB added
RxNorm normalized name: EMB
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMB added to chemotherapy regimen
Trial: 983179
Drug: EMB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMB and another combination in 54 new cases
Trial: 983179
Drug: RMP added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RMP added to treatment in 20 new cases
Trial: 29311704
Drug: Kinkeliba (Combretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinkeliba (Combretum micranthum) 190 mg × 2/day
Trial: 29311704
Drug: Bissap (Hibiscus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bissap (Hibiscus sabdariffa) 320 mg × 2/day
Trial: 9850359
Drug: HFA-BDP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP 400 micrograms day-1 (delivered as four actuations of 50 micrograms twice daily)
Trial: 9850359
Drug: HFA-BDP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP 400 micrograms day-1 (delivered as two actuations of 100 micrograms twice daily)
Trial: 9850359
Drug: HFA-BDP (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP (both dosing regimens)
Trial: 7866911
Drug: Experimental diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental diet (150 mg calcium and 1600 mg phosphorus daily)
Trial: 7866911
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum intact parathyroid hormone (PTH) concentration
Trial: 2670633
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (1 g/day)